Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 303M
-0.14%+4.33%+9.88%+31.73% 48.01B
-1.69%+1.48%+53.02%+33.59% 45.27B
+2.56%+7.34%+382.17%+594.81% 42.84B
+0.24%+2.85%+9.78%+89.54% 40.93B
-0.62%-1.11%+4.70%+46.02% 29.6B
-0.28%+1.07%+26.83%+152.91% 17.32B
-0.46%+1.20%+26.78%+41.32% 15.34B
-2.21%-4.70% - - 15.15B
+3.37%+9.21%+9.93% - 14.84B
Average +0.64%+1.60%+65.39%+141.42% 29.92B
Weighted average by Cap. +0.09%+1.77%+81.87%+153.92%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-